<DOC>
	<DOCNO>NCT01039103</DOCNO>
	<brief_summary>Patients acute exacerbation Relapsing-Remitting Multiple Sclerosis Clinically Isolated Syndrome receive either one single infusion Nanocort three daily infusion SoluMedrol . Main objective ass occurrence new gadolinium-enhanced T1-weighted lesion week 8 v week 1 treatment .</brief_summary>
	<brief_title>Nanocort Acute Exacerbation Relapsing-Remitting Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>INCLUSION criterion Diagnosis RRMS ( per McDonald criterion , 2005 ) dissemination time space OR diagnosis CIS confirm MRI . Patients CIS optic neuritis exclude study A maximum Expanded Disability Status Scale ( EDSS ) score â‰¤ 6 New neurological symptom exacerbation prior neurological symptom 24 hour duration &lt; 7 day duration , verify neurological examination EXCLUSION criterion : Primary progressive MS . Secondary progressive MS without superimposed relapse . Received systemic corticosteroid within 4 week screen treatment MS condition . contraindication treatment ( systemic ) corticosteroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>PEG-liposomal prednisolone sodium phosphate</keyword>
</DOC>